Navigation Links
DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
Date:10/1/2007

MUNICH, Germany, October 1 /PRNewswire/ --

- New Product Under Development for the Treatment of High Blood Pressure

- Approval Requested in 28 European Countries

DAIICHI SANKYO EUROPE GmbH has applied in 28 European countries for approval of a new antihypertensive medication. It is a fixed combination (CS-8663) of two substances, the angiotensin receptor blocker (ARB) Olmesartan and the calcium antagonist Amlodipin.

When approved, the new combination for treatment of essential hypertension is designed for use in patients whose blood pressure cannot be adequately controlled through therapy with the respective monopreparation. In clinical trials the combination of Olmesartan / Amlodipin (CS-8663) has shown a significant lowering of blood pressure. In the new fixed combination, two complementary therapeutic approaches are combined: blocking of the angiotensin II receptor and blocking of the calcium channel. Olmesartan is already being marketed by DAIICHI SANKYO and is the angiotensin receptor blocker with the greatest sales growth in Europe(1). Amlodipin is one of the most frequently used calcium antagonists in many European countries.

"Hypertension is currently viewed as the number one cause of death. Most patients need two or even more medications to normalise their blood pressure. The new fixed combination has proved to be effective and well tolerated in a large number of patients. That also applies to patients who have very high blood pressure at the start of therapy," says Dr Petra Laeis, Head of Clinical Research at DAIICHI SANKYO EUROPE. "The combination of the two well-known agents Olmesartan and Amlodipin in one tablet gives doctors another effective treatment option for hypertension, which can lead to better results because patients are more likely to use it faithfully," continues Dr Laeis.

DAIICHI SANKYO is a worldwide, research-oriented pharmaceutical company, created through the merger of the two traditional Japanese enterprises Daiichi and Sankyo. The company is one of the world's leading manufacturers of medication. The company's research activities focus on the areas of cardiovascular, haematology, diabetes, anti-infectives and cancer. DAIICHI SANKYO has its European headquarters in Munich.

For additional information, please visit our website at

http://www.daiichi-sankyo.eu/

(1) Source: IMS MIDAS Juli 2007

Contact:

Dr Andrea Jager

Vice Director Operative Marketing

Telephone +49-(0)89-78-08-454

andrea.jaeger@daiichi-sankyo.eu


'/>"/>
SOURCE DAIICHI SANKYO EUROPE GmbH
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
2. Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
3. A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors)
4. Merge launches diagnostic mammography workstation in Europe
5. Mirus granted European patent for gene therapy
6. Johnson Controls to expand in Europe
7. Innovation thrives in Europe
8. Info security group announces first Eastern European chapter
9. EMD Biosciences partners with European biotech company
10. Third Wave lands European distribution deal, reports high earnings
11. Third Wave seeks approval of Cystic Fibrosis test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  Driven by consumers, preference towards more natural ... growing categories, finds the recently published U.S. volume ... Multi-regional Market Analysis and Opportunities study by ... "Biotechnology actives are derived from natural ... for skin and hair care applications," explains ...
(Date:2/24/2017)... Pa., Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), the ... laboratory and production customers, today reported its financial results for ... Highlights: 4Q16 record quarterly ... 1.0% on an organic basis. ... an organic basis, while the Americas net sales increased 2.5%, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Drug Discovery Services portfolio to include an array of biochemical analyses critical ... reliable data to drive their hit-to-lead and SAR programs, including inhibitor potency and ...
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, ... strange place for a head lice treatment salon to set ... a Tuscan restaurant and a French bistro on E Madison ... "We aren,t just any old lice clinic, we pride ourselves ... comfortable, and release some of the stigma associated with lice. ...
Breaking Biology Technology:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... , its innovative, highly flexible and award winning eClinical ... customers. iMedNet is a proven Software-as-a-Service (SaaS) ... Data Capture (EDC), but also delivers an entire suite ...
(Date:2/6/2017)... , Feb. 6, 2017 According ... security are driving border authorities to continue to ... reports there are 2143 Automated Border Control (ABC) ... currently deployed at more than 163 ports of ... 2013 to 2016 achieving a combined CAGR of ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):